We blocked the tumor anabolism with orlistat, lonidamine and DON (6-Diazo-5-oxo-L-norleucine) (OLD drug scheme) to inhibit FASN, HK2 and GLS, respectively, whereas with the combination of anti-catabolic drugs we aimed to ameliorate cancer cachexia. Here, FASN is linked to cancer.